At what enterprise value was STERIMED acquired in 2019?

You can find the full valuation details of STERIMED on mynth capital. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 15.6x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of STERIMED when it was acquired by SAGARD?

The exact EV/EBITDA multiple for STERIMED is available on mynth capital. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 15.6x. Join our community for free to access full valuation data and industry trends.

When was STERIMED acquired by SAGARD?

STERIMED was acquired by SAGARD in 2019.

What was the revenue of STERIMED at the time of the deal?

The revenue of STERIMED at the time of the deal is estimated to be in the range of 100M - 200M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the STERIMED acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the STERIMED deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.cfnews.net/L-actualite/International/Operations/Build-up-International/Sterimed-complete-son-package-au-Royaume-Uni-434663

← DATABASE

Home Database Healthcare & PharmaSTERIMED

09/2019

STERIMED acquired by SAGARD

FRANCE Life Sciences / Medical Devices / Medical Consumables REV 100M - 200M EUR

Context

Sterimed, a global leader in medical sterilization packaging, has entered into exclusive negotiations with Sagard to organize a secondary LBO. This transaction facilitates the exit of Meeschaert Capital Partners, which held a majority stake since 2016 following the group's spin-off from ArjoWiggins. The current management team, led by CEO Thibaut Hyvernat, will remain significantly invested in this new chapter.

STERIMED, which reported an EBITDA margin of in 2018, is valued in this transaction at an EV/EBITDA multiple of , a level to compare with the average currently observed in the Healthcare & Pharma sector (15.6x).

-> Deep-dive in Healthcare & Pharma market trends

Target

A global leader in the manufacturing of medical sterilization packaging solutions. Sterimed designs, produces, and markets high-performance packaging materials (paper, film, and complex materials) used by medical device manufacturers and hospitals to maintain the sterility of instruments. The group operates several production sites worldwide (France, China, USA, Mexico).

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2018

2017

Other operations with STERIMED

List of similar M&A transactions (Date, Acquirer, Target, Country, Sub-sector)
Date	Acquirer	Target	Country	Sector
05/2026	STERIMED	SIMAGEC	FRANCE	Packaging & Containers
04/2025	IK PARTNERS	STERIMED	FRANCE	Medical Consumables

REFERENCES

Revenue range: 100M - 200M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of STERIMED by SAGARD are reserved for mynth community members. Register for free to unlock full data.

Authors: This transaction was contributed by a verified mynth contributor and cross-checked against available transaction documents and official company communications.

Target: sterimed

Acquirer: sagard